PE-backed Neopharmed Gentili buys Orladeyo

Orladeyo is the first oral, once-daily plasma kallikrein inhibitor indicated for the treatment of hereditary angioedema.

27 June 2025•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Europe North America US Healthcare Briefs